Number of medicinal cannabis prescriptions in Australia - how many prescribers

Number of Medicinal cannabis Prescriptions and Prescribers in Australia

What is the current number of medicinal cannabis prescriptions in Australia so far?

In just a few years, the number of medicinal cannabis prescriptions through the Special Access Scheme B (SAS-B) has grown substantially. It still represents a small percentage of the overall Australian population who state they rely on cannabis for medicinal purposes. Only 3 or 4 out of every 10 people who report using cannabis for medicinal purposes obtain a legal prescription for high-quality products through the scheme.

Five years ago, not long after the new scheme formally began, the number of trained, registered providers and the number of GP approvals for cannabis medicines were low.

  • Back in 2019, there were just 144 doctors authorised to issue prescriptions for medicinal cannabis under the TGA’s Special Access Scheme (SAS-B).
  • Before the start of 2019, there were barely over 1,000 prescriptions issued under the SAS-B.
  • By the end of 2019, that number was said to have reached 28,000 prescription approvals:
    • Involving more than 1,400 trained and registered providers who could legally prescribe this type of product.
    • The majority of these registered providers were GPs.

 

By 2021, over 70,000 SAS-B prescriptions had been approved and by the end of 2022/start of 2023, that number is somewhere in the vicinity of 326,000.

Since the pandemic, many more doctors have trained and registered to provide these products to patients.

  • Many doctors trained to prescribe medicinal cannabis, and registered with the TGA as a provider, only during the past two years.
  • These registrations and prescriptions occurred not long after the pandemic began.
  • However, this growth may relate more to the evolution and maturation of the SAS-B program than to the pandemic stressors, but these stressors likely exacerbated mental health conditions as well as physical pain conditions (with the two intricately intertwined).

By the end of 2022, reports indicated over 250,00o medicinal cannabis prescriptions had been approved in Australia.

There are now around 2,000 (potentially up to 4,600) registered prescribers. Over 100,000 patients formally rely on cannabis medications obtained through the Special Access Scheme (SAS-B).

Are you a patient? Please participate in the University of Sydney survey (anonymous) by clicking here.

Prescription growth for cannabis-based medicines

Prescription growth statistics & early history of SAS-B

  • 2019 was a pivotal growth year in various cannabis sectors, with multiple jurisdictions decriminalising cannabis use around the globe.
  • The number of Medicinal Cannabis prescriptions in Australia was estimated at 10,000 prescriptions by around July 2019.
  • This represented a significant increase from the ~3,100 SAS-B prescriptions for medicinal cannabis reported prior to 2019.
  • That early prescription number represented less than 5% of the reported cannabis users in Australia.
  • Over 95% of cannabis use in Australia was still obtained and used illegally (via the ‘black market’).

By mid-2021, there were around 14,000 prescriptions for cannabis medicines approved through the Special Access Scheme (SAS-B). Fast forward to 2022, with reports indicating over 300,000 prescription approvals under the SAS-B and at least 100,000 patients using cannabis-based medicines as a treatment regime for various conditions.

 Note: This article was originally published in June 2019 and has been updated on January 16, 2023.

Medicinal cannabis in Australia vs illicit drugs

Even though the scheme is useful, many Australian cannabis users are still buying and possessing cannabis illegally for medicinal purposes as well as recreational use purposes. Prescription medicines are, by their nature, generally more expensive to manufacture and purchase than street drugs, which are low-quality and contaminated with various bacteria including ‘human poo’.

Comparisons to other countries:


Medicinal Cannabis prescription trends | Changes in the number of SAS approvals for cannabis medications

The Table below illustrates changes in SAS Category B approval statistics for medicinal cannabis prescriptions in Australia.

  • As of 31 May 2019, the TGA approved over 7,700 SAS Category B applications for unapproved medicinal cannabis products.
  • A breakdown of the number of SAS Category B approvals by month (June 2018 to May 2019) is shown below

History of prescription growth in early SAS-B stages (monthly figures)

Monthly prescriptions Number of SAS Category B approvals
June 2018 146
July 2018 188
August 2018 229
September 2018 237
October 2018 331
November 2018 567
December 2018 490
January 2019 670
February 2019 738
March 2019 1040
April 2019 1109
May 2019 1374
September 2021 13,666

Source: https://www.tga.gov.au/medicinal-cannabis

Please note:  These figures are reported to represent the number of SAS Category B approvals only.

Interesting Facts:

  • The TGA received its first known medicinal cannabis SAS application in 1992.
  • Most cannabis prescription approvals have occurred since 2016, with a nearly 200% increase in the first few months of 2019.

Who can help to start a medicinal cannabis production and export business?

PharmOut’s cannabis consultants can assist you with licensing applications, medicinal marijuana processing and regulatory requirements for GMP / EU GMP (PIC/S).

Our pharmaceutical facility design architects, cleanroom validation, testing and processing engineers are experts in assisting cultivators and medicinal cannabis manufacturers with environmentally-minded designs for efficiency and GMP compliance. Contact PharmOut with your enquiry or view the top 10 medicinal cannabis blogs.


Recreational vs Medicinal Use | An overview of GMP

Medicinal cannabis suppliers are subjected to strict cultivation and production licencing requirement, including secure record-keeping systems, regular testing and reporting, and frequent GMP auditing.

GMP helps ensure a quality, consistent product that is free from harmful contaminants that could seriously harm vulnerable individuals seeking these types of medications.

EU GMP / Australian GMP compliance for medicinal cannabis production is important because:

    • Many individuals wanting to access medicinal cannabis may have compromised immune systems, e.g. cancer patients or people with HIV
    • This compromised immunity means the purity of their cannabis medications is paramount to their safety; it is feasible that if a pharmaceutical product contained impurities, it could prove fatal to immune-compromised patients

Cannabis that is not GMP pharmaceutical-grade is of unproven purity, questionable quality, and varying strengths; substandard medicines could harm vulnerable patients with compromised immune systems.

Number of medicinal cannabis prescribers in Australia - number of Doctors prescribing cannabis

This is one reason that EU/GMP must be followed at all steps of producing pharmaceutical cannabis products for domestic and international products.


Cannabis pharmaceuticals must meet TGO93 standards and/or EU/GMP.

The problem with the illegal use of cannabis by patients with serious health conditions:

  • Illegally grown or imported cannabis products lack isolation of the medicinal components in cannabis plants
  • They are a risky and inconsistent source of cannabinoids and/or THC

Online cannabis medication providers are already targeting individuals with fake cannabis medications, which are highly unlikely to have any valid therapeutic effects

Illegal cannabis also carries serious repercussions for importation, exportation, possession and use in Australia.

Pharmaceutical grade cannabis must meet TGO 93 standard. That noted, it remains an unapproved medication that is only available through Special Access Schemes (SAS).


Getting a prescription for medicinal cannabis in Australia

How easy — or how difficult — is it to get a prescription for medicinal cannabis?

Authorisation to prescribe unapproved cannabis medicines is monitored at the STATE level. This can vary from state to state.

  • Gaining access for medicinal cannabis medications has reportedly been challenging for patients.
  • They are encouraged to see their GP, who may — or may not — already applied for approval as an Authorised Prescriber or SAS prescriber.
  • States are in charge of approving the prescribing medical provider (some applications can be done online, but this can take some time); AND
  • Applications for Special Access for individual patients must also be submitted (said to take at least 2 days).

GPs and other medical professionals wanting to supply medicinal cannabis to patients need to apply one of two ways: either under the Special Access Scheme or by making an application under the Authorised Prescriber Scheme.

Many doctors remain hesitant to prescribe these medications and/or remain unfamiliar with their potential uses, dosage recommendations and effects.

Read more about the need for further clinical research studies for cannabis.


Which health conditions might benefit from medicinal cannabis?

TGA Special Access Schemes recognise that cannabis medications, while unapproved by the TGA due to insufficient efficacy and safety data, MIGHT have benefit for the following conditions:

  • chemotherapy-induced nausea and vomiting
  • refractory paediatric epilepsy
  • palliative care indications
  • cancer pain
  • neuropathic pain
  • spasticity from neurological conditions
  • anorexia and wasting associated with chronic illness (such as cancer)
  • others not listed above

Source: https://www.tga.gov.au/medicinal-cannabis

Overseas studies also support its potential efficacy in medication-assisted therapies, such as for PTSD, Anxiety and Depression; and Fibromyalgia.


Number of Medical Cannabis Prescribers in Australia

Nearly any Doctor can prescribe Medicinal Cannabis through the Special Access Scheme, once they’ve been approved as an Authorised Prescriber.

Many, however, remain reluctant to do so.  This is partially due to unfamiliarity with the medications and a lack of consistent evidence in published trials.

  • Many of the published cannabis-based research trials had low-quality evidence in relation to efficacy, dosing requirements and side effects.
  • Inconsistent or inconclusive research findings hence remain a concern for prescribing Doctors, given these medicines are not yet TGA approved.

Inconclusive findings in systematic reviews are likely resulting from small study sizes or insufficiently rigorous trials.

That noted, worldwide prohibition of herbal medications prevented research from occurring for decades.  Efficacy and safety research is expected to increase, in quality and quantity, with Federal legislation changing around the world.  In fact, many top Universities – the latest being the University of Pennsylvania – are well into their research projects with new funding and study ethics approvals.

In Australia, NSW and Queensland both started research trials within 12 months after Federal Laws were changed, allowing easier access to cannabis-based medications.

There remains, however, a chasm between wanting to investigate innovative medicines and protecting the safety of study participants as well as research Sponsors in the face of contradicting, or insufficient, evidence.

There’s high excitement in Australia about the potential use of cannabinoid medications to treat various illnesses, including PTSD, opioid addictions and chronic pain.


However, HREC approvals in Australia have often been delayed, or turned down, to the frustration of medical researchers wanting to explore different applications for medicinal cannabis formulations. Attaining quality TGO93 cannabis medication supplies remains a challenge.


Doctors and patients have personal and professional liability for prescribing unapproved Medications

Another reason some GPs remain hesitant to prescribe medicinal cannabis arises from the fact that these medications, while available through Special Access Schemes, are not yet on the TGA approved medication list.

Until further studies provide more evidence for the efficacy and safety of these medications, Doctors carry a degree of professional liability for prescribing the medications.

  • There also remains a stigma about these medications.
  • Most of the stigma persists due to a lack of exploration into the scientific differences in various cannabis-derived medications vs recreational use ‘pot’ or ‘weed.’  
  • Scientists and medical researchers are hoping to better educate patients, doctors, journalists and policy-makers about the differences between illegal vs highly-regulated, pharmaceutical-grade cannabis products produced using GMP (good manufacturing processes) and record-keeping systems

Additionally, Medical Professionals and prescribers simply lack adequate training in understanding specific conditions for which cannabinoid medications might have a positive effect.


The two main types of medical cannabis prescriptions are those that contain delta-9 tetrahydrocannabinol (THC), the psychoactive component; and those that contain non-psychoactive cannabinoids (CBD).

The level of THC determines if the cannabis medication is listed as a Schedule 8 or Schedule 4 medication.

Excerpt: In Victoria, for example, the CBD content of Schedule 4 medicinal cannabis products must be 98 per cent of the total cannabinoid content (e.g. A CBD to ‘other cannabinoid’ ratio of 49:1). This means other cannabinoids must be less than 2% of the medication content.

Cannabis medications with other components, such as over 2% THC, are classed as Schedule 8 controlled drugs.

Source: https://www2.health.vic.gov.au/public-health/drugs-and-poisons/medicinal-cannabis/health-professionals 


Number of TGA Registered medicinal cannabis products

  • Only one (1) medicinal cannabis product, Nabiximols (Sativex®), is listed on the ARTG as a Schedule 8 controlled drug (as of June 2019) 
  • The approved indication for Nabiximols (Sativex®) is:  ‘treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.’

Cannabis-based medication permits and/or patient access approval processes, in relation to Schedule 8 drug prescriptions, vary from State to State.


Journal Publications and suggested reading

RCT Evidence base for Cannabis Medications (Research Findings)

Systematic Reviews

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence
Authors: Emily Stockings, Dino Zagic, Gabrielle Campbell, Megan Weier, Wayne D Hall, Suzanne Nielsen, Geoffrey K Herkes, Michael Farrell, Louisa Degenhardt

The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews
Authors: Suzanne Nielsen, Rada Germanos, Megan Weier, John Pollard, Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Michael Farrell

Systematic review and meta-analysis of cannabinoids in palliative medicine
Authors: Martin Mücke, Megan Weier, Christopher Carter, Jan Copeland, Louisa Degenhardt, Henning Cuhls, Lukas Radbruch, Winfried Häuser, Rupert Conrad

Access to medicinal cannabis products for Consumers

Consumers, GPs, medical professionals and manufacturers can find more information on the Special Access Scheme (SAS) and Authorised Prescriber Scheme at: Access to medicinal cannabis products.

Page last updated: December 2022